Seeking Alpha
View as an RSS Feed

Long Term Bio  

View Long Term Bio's Articles BY TICKER:
  • Ohr Pharmaceutical: Undervalued Biotech Set To Possibly Challenge Regeneron's Eylea Drug
    Fri, Mar. 27 OHRP 7 Comments

    Summary

    • Company reported positive Phase 2 results in Wet Age-related Macular degeneration.
    • Company uses a different method of targeting Wet-Age-related Macular degeneration.
    • Ohr Pharmaceutical has the ability to eventually overtake Regeneron's Eylea drug in sales.
  • BIND Therapeutics Offers Great Potential With Upcoming Catalyst
    Nov. 13, 2014 BIND 5 Comments

    Summary

    • An upcoming catalyst result in lung cancer provides for excellent upside potential.
    • The Accurin technology attaches to and enhances multiple therapeutic payloads leading to many potential partnerships.
    • Company has already established a large amount of partnerships with big pharmaceutical companies further validating the Accurin technology.
  • Tokai Pharmaceuticals Comes To Market: Is It Worth Buying?
    Sep. 29, 2014 TKAI 3 Comments

    Summary

    • Tokai Pharmaceuticals provides investors with a tremendous buying opportunity after its big decline since its IPO.
    • Tokai sets itself apart from other Castration-resistant prostate cancer biotech companies by creating a unique compound.
    • Tokai has the opportunity to make investors a lot of money in the future if it is successful with its Galeterone compound.
    • Investors don't have to worry about near-term dilution risk as the company has plenty of cash since it just did its IPO recently.
    • Success shown thus far in phase 2 trial patients indicates more likely than not that phase 3 should see great results.
  • RXi Pharmaceuticals: Interview With CEO Post-Phase 2a Interim Data
    Sep. 23, 2014 RXII 14 Comments

    Summary

    • Interview With CEO enlightens investors on current and future trials.
    • RXi has many other compounds and catalysts that investors can look forward to in the coming months.
    • RXi released initial data for hypertrophic scars in Phase 2a, that are promising for the future.
    • RXi can use its sd-rxRNA platform and apply it to many different disease areas.
  • Orexigen Therapeutics Wins Contrave Approval But Investors Should Stay Away
    Sep. 16, 2014 OREX 30 Comments

    Summary

    • Orexigen Therapeutics announced September 11th 2014 that the company received FDA Approval for Contrave.
    • Stock plummeted on the day of Contrave Approval as investors headed for the exit.
    • Selloff in company stock could be because of a crowded space in the obesity market.
    • Many investors remain skeptical on obesity market as it faces an uphill battle.
    • Additional costs are required by the FDA to allow Contrave to be marketed in the U.S.
  • Is GW Pharmaceuticals Still A Buy After A Big Run-Up?
    Aug. 8, 2014 GWPH 14 Comments

    Summary

    • Even after the recent share price increase, investors still have the opportunity to capitalize on future catalysts.
    • GW Pharmaceuticals sets itself apart from competitors with its new cannibinoid platform technology that is difficult to reproduce.
    • Phase 2 results validate the technology platform further, and also validate future revenue to be made in the seizure market.
    • Cannabis plants provides 70 or more molecules that can be used to target many different diseases.
    • The company already has an approved drug on the market known as Sativex, which is already generating a substantial amount of revenue.
  • Pfizer Has It All Wrong, Should Look Into New Viable Acquisitions
    Jul. 3, 2014 PFE 19 Comments

    Summary

    • Pfizer needs to leave AstraZeneca alone and consider other options for acquisition.
    • Celgene should be considered for acquisition because of its cancer-fighting compounds and arthritis compounds.
    • Gilead Sciences should be considered because of its blockbuster hepatitis C drug, Sovaldi, and HIV drug compounds.
    • Pfizer can do better acquiring mid-size biotechnology companies that have steady future growth.
    • Pfizer needs to help its diminishing pipeline.
  • Endocyte Fails Ovarian Cancer Trial, Now What?
    Jun. 11, 2014 ECYT 41 Comments

    Summary

    • Endocyte fails combination of Vintafolide with PLD, but gives investors an opportunity for a long-term buy after big drop.
    • Endocyte shows a different combination of Vintafolide together with docetaxel achieves primary endpoint for Phase II study targeting NSCLC.
    • Merck still has the established partnership, despite Vintafolide failing with one combination of a chemotherapy drug.
    • NSCLC holds more value for Endocyte, and as such is a more important trial for the future of the company.
  • Why I'm Short Synthetic Biologics After Phase II Relapsing-Remitting MS Data
    May. 19, 2014 SYN 48 Comments

    Summary

    • Preliminary results of RRMS patients showed improvement at 12 months, but failed to show statistical significance at 24 months.
    • Dismissal of Phase II RRMS results by investors allows for an opportunity to short the stock.
    • Reluctance to show p-values in initial press release shows lack of confidence of trial results.
    • Steve Kanzer, 10% owner, selling 5 million shares at a low share price of $1.43 per share shows lack of confidence in trial.
    • Attempting to run a Phase III trial after obtaining a non-significant p-value at month 24 of p = .1537 is very risky.
  • Cytokinetics Fails Lou Gehrig's Trial But Still Holds Value With Cardiac Drug
    Apr. 29, 2014 CYTK 4 Comments

    Summary

    • BENEFIT-ALS trail failure gives investors opportunity to take a risk on the Cardiac drug at a lower share price.
    • Positive outcome for phase 2 COSMIC-HF will push omecamtiv mecarbil compound moving forward into a phase 3 trial.
    • The Positive secondary endpoint for ATOMIC-AHF still gives positive hope for omecamtiv mecarbil to help patients with heart failure.
    • Positive phase 2 results from COSMIC-HF is a catalyst for share price appreciation..
  • Prana Biotechnology Is Still A Short After Recent Alzheimer's Failure
    Apr. 14, 2014 PRAN 14 Comments

    Summary

    • Prana still is a good short candidate, because the PBT2 compound has failed to produce substantial efficacy in two Phase II trials.
    • Setting up the Phase II trial with safety as the primary endpoint showed lack of confidence in a positive clinical outcome.
    • Phase III Trial for Huntington's disease could take years to test, allowing the possibility to short the stock before the trial readout.
  • Opexa Therapeutics: A Long-Term Perspective For Price Appreciation
    Mar. 10, 2014 OPXA 6 Comments

    Summary

    • Tcelna has the opportunity to provide patients with a first in line therapy for Secondary Progressive Multiple Sclerosis that is not toxic.
    • Opexa investors that remain long term have the ability to reap huge rewards if the phase 2b trial comes out with positive efficacy.
    • Opexa stands to make $7 billion dollars in sales with Tcelna, and could be used for other disease indications.
  • Benitec: An Undiscovered Biotechnology With A Twist
    Feb. 27, 2014 BNIKF 33 Comments
  • Arrowhead: A Functional Cure For The Hepatitis B Virus
    Feb. 19, 2014 ARWR 10 Comments
  • Tekmira Pharmaceuticals: A Technology Delivering Superstar
    Feb. 10, 2014 TKMR 24 Comments
  • Idera Pharmaceuticals: Set To Ride A 200% Gain In 2014
       • Jan. 31, 2014 IDRA 15 Comments
  • Novavax:A Biotech Story Set To Double In 2014
       • Jan. 13, 2014 NVAX 48 Comments
  • Rexahn: A Turn Around Story For 2014
       • Dec. 22, 2013 RNN 29 Comments
  • Cellceutix: An Undiscovered Company Set To Rise In 2014
       • Dec. 16, 2013 CTIX 16 Comments
  • Merrimack: Opportunity To Increase Share Price By 100% In 2014
    Dec. 9, 2013 MACK 10 Comments
  • Rxi Pharmaceuticals, Significant Upside Of 300% Is Expected In Coming Months
       • Dec. 3, 2013 RXII 20 Comments